These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 3299374)

  • 1. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors.
    Billings PC; Carew JA; Keller-McGandy CE; Goldberg AL; Kennedy AR
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4801-5. PubMed ID: 3299374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a soluble enzyme from C3H/10T1/2 cells which is inhibited by the Bowman-Birk proteinase inhibitor.
    Fagan JM; Waxman L
    Biochem Biophys Res Commun; 1991 Aug; 178(3):856-61. PubMed ID: 1872865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR
    Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
    Billings PC; Habres JM
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3120-4. PubMed ID: 1557421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor.
    Billings PC; Habres JM; Liao DC; Tuttle SW
    Cancer Res; 1991 Oct; 51(20):5539-43. PubMed ID: 1913672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors.
    Habres JM; Billings PC
    Cancer Lett; 1992 Apr; 63(2):135-42. PubMed ID: 1562990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of the potato-derived chymotrypsin inhibitor with C3H/10T1/2 cells.
    Billings PC; Jin T; Ohnishi N; Liao DC; Habres JM
    Carcinogenesis; 1991 Apr; 12(4):653-7. PubMed ID: 2013129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a proteolytic activity which responds to anticarcinogenic protease inhibitors in C3H-10T1/2 cells.
    Carew JA; Kennedy AR
    Cancer Lett; 1990 Feb; 49(2):153-63. PubMed ID: 2306709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of novel trypsin-like serine proteases from mouse spleen.
    Fukusen N; Aoki Y
    J Biochem; 1996 Apr; 119(4):633-8. PubMed ID: 8743562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of oral carcinogenesis by a protease inhibitor.
    Messadi DV; Billings P; Shklar G; Kennedy AR
    J Natl Cancer Inst; 1986 Mar; 76(3):447-52. PubMed ID: 3081747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor.
    Wan XS; Meyskens FL; Armstrong WB; Taylor TH; Kennedy AR
    Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):601-8. PubMed ID: 10428197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of radiation-induced transformation of C3H/10T1/2 cells by specific protease substrates.
    Billings PC; Habres JM; Kennedy AR
    Carcinogenesis; 1990 Feb; 11(2):329-32. PubMed ID: 2406034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and partial characterization of a chymostatin-sensitive endopeptidase in transformed fibroblasts.
    O'Donnell-Tormey J; Quigley JP
    Proc Natl Acad Sci U S A; 1983 Jan; 80(2):344-8. PubMed ID: 6300832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of protease inhibitors on c-myc expression in normal and transformed C3H 10T1/2 cell lines.
    Chang JD; Li JH; Billings PC; Kennedy AR
    Mol Carcinog; 1990; 3(4):226-32. PubMed ID: 1698382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR
    Int J Radiat Biol; 2023; 99(6):882-890. PubMed ID: 34325613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor.
    St Clair WH
    Carcinogenesis; 1991 May; 12(5):935-7. PubMed ID: 2029760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
    Moy LY; Billings PC
    Cancer Lett; 1994 Oct; 85(2):205-10. PubMed ID: 7954338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential mechanisms of antitumorigenesis by protease inhibitors.
    Kennedy AR
    Basic Life Sci; 1993; 61():301-7. PubMed ID: 8304942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the active site of human multicatalytic proteinase.
    Mason RW
    Biochem J; 1990 Jan; 265(2):479-84. PubMed ID: 2302179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.